Dr. Michael Gnant
is Professor of Surgery and Director of the Department of Surgery at the Medical University of Vienna, Austria, where he also serves as President of the Austrian Breast and Colorectal Cancer Study Group.
His medical career began in 1988 when he graduated in medicine in Vienna after studying in Vienna and Munich. He then specialized in surgery (1994) and surgical oncology. In 1997 and 1998 he worked as a Visiting Scientist at the National Cancer Institute, NIH, Bethesda, USA. In 2004, he became Full Professor at the Medical University of Vienna, where he also heads the Breast Health Center. In 2005, he was elected President of the Austrian Breast & Colorectal Cancer Study Group (ABCSG). Since 2014, he serves as Chairman and Director of the Department of Surgery at Medical University, where he also was elected President of the University’s Senate.
Professor Gnant has published more than 400 original papers in peer-reviewed journals, including 97 as first author, and 113 as senior/corresponding author. His cumulative impact factor is more than 2.800, with >12.000 citations, an average citation index of 32, and an h-index of 45. He has has given numerous lectures at national and international meetings, including Plenary and Highlight Lectures at ASCO (2005, 2014, 2015), EBCC (2010, 2012, 2014, 2016), and SABCS (2013). In addition, he has been the recipient of multiple national and international awards.
He co-leads the Comprehensive Cancer Center Vienna and serves on the famous St. Gallen Consensus Panel for Early Breast Cancer since 2007 (Co-chairing the event after it has moved to Vienna in 2015). He was elected to the European Academy of Science and Arts in 2009. Among other honors, he is a Fellow of the American College of Surgeons.
Dr. Gnant’s research interests include several fields of surgical oncology, in particular breast, colorectal and pancreatic cancer, immunotherapy using antibodies, vaccination with dendritic cells, endocrine intervention, dormant tumor cells, the use of bone targeted treatments in order to silence tumor micrometastases and prevent osteoporosis, and pathway directed therapies such as mTOR and CDK 4/6 inhibition. He has been the Principal Investigator of more than 30 clinical trials, and currently global Co-Chair of the adjuvant PALLAS study.
He is involved in many scientific societies, including the American Society of Clinical Oncology, American Association of Cancer Research, ACS, Breast International Group, EUSOMA, and the European Society of Surgical Oncology. Among other activities, he currently serves as an Executive Board member of B.I.G. and for the Center of Excellence for Clinical and Experimental Oncology in Vienna, independent Reviewer and IDMC member for the European Organization for Research and Treatment of Cancer, the UICC, the German Cancer League, and other international bodies, and Scientific Reviewer and Process Evaluator for the European Union. He has been a member and assessor of the ethical committee of the Vienna Medical University since 2000.
In addition to these responsibilities, he serves as Editor-in-Chief as well as on editorial boards for several journals and serves as reviewer for many peer-reviewed journals, including The Lancet, The New England Journal of Medicine, Journal of the National Cancer Institute, JAMA, Clinical Cancer Research, International Journal of Cancer, The Lancet Oncology, Journal of Clinical Oncology, Breast Cancer Research and Treatment, Annals of Oncology, and many others.